Paul Strickland Scanner Centre and Department of Oncology, Mount Vernon Hospital, Middlesex, HA6 2RN, England, UK.
Clin Nucl Med. 2012 Nov;37(11):1115-6. doi: 10.1097/RLU.0b013e318266cbdb.
18F-FDG PET/CT plays an important role in the management of non-small-cell lung cancers (NSCLC). The treatment options for NSCLC depend upon the initial staging of the disease. The authors report a case with a potential pitfall of overlooking a site of FDG uptake as radiopharmaceutical extravasation at an injection site. The PET/CT demonstrated a T2a N2 bronchial carcinoma, with a solitary focus of FDG uptake at the left antecubital fossa where FDG was administered. Careful interpretation of the images reveals a solitary skeletal metastasis in the left proximal ulna, which makes the disease stage IV rather than IIIA, leading to a significant difference in treatment.
18F-FDG PET/CT 在非小细胞肺癌（NSCLC）的管理中发挥着重要作用。NSCLC 的治疗选择取决于疾病的初始分期。作者报告了一例潜在的陷阱，即忽略了放射性药物外渗部位的 FDG 摄取部位。PET/CT 显示 T2aN2 支气管癌，在左肘前窝给予 FDG 的部位有一个孤立的 FDG 摄取焦点。仔细解读图像显示左侧近侧尺骨有一个孤立的骨转移灶，这使得疾病分期为 IV 期而不是 IIIA 期，导致治疗方法有显著差异。
